Long-Acting Treatment in Adolescents (LATA)

Summary

The LATA trial will find out if taking a long-acting injectable form of HIV medicines, called cabotegravir and rilpivirine, every 2 month works as well as taking tablet HIV medicines every day in young people aged 12-19 years of age. The trial is organised by an international group of researchers from Europe and Africa, and will include 460 young people, from Kenya, South Africa, Uganda and Zimbabwe.

Timeline

Start

2023-06-22

Primary completion

2025-03

Completion

2026-03

Publications

• Anena D, Chappell E, Nazzinda R, Kiilu C, Chitsamatanga M, Arumugam T, Green A, Kityo Mutuluuza C, Bwakura-Dangarembizi M, Siika A, Archary M, Jafta L, Namukwaya S, Seeley J, Akabwai G, Mugerwa H, Bevers L, Burger D, Walker S, Bamford A, South A, Apoto N, Bush M, Thomason MJ, Spittle B, Ford D, Kekitiinwa AR, Pett SL; LATA Trial Team. Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa. Contemp Clin Trials. 2026 Mar;162:108213. doi: 10.1016/j.cct.2025.108213. Epub 2026 Jan 7.

Drugs

Indications